Leerink Partnrs Has Positive Outlook of ASND FY2024 Earnings

Ascendis Pharma A/S (NASDAQ:ASND) – Equities researchers at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for shares of Ascendis Pharma A/S in a note issued to investors on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now anticipates that the biotechnology company will earn ($6.44) per share for the year, up from their previous estimate of ($6.50). The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($7.11) per share. Leerink Partnrs also issued estimates for Ascendis Pharma A/S’s Q4 2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($1.90) EPS, Q2 2025 earnings at ($1.81) EPS, Q3 2025 earnings at ($1.74) EPS, Q4 2025 earnings at ($1.66) EPS, FY2025 earnings at ($7.12) EPS and FY2026 earnings at ($2.00) EPS.

A number of other equities research analysts have also recently weighed in on the company. JPMorgan Chase & Co. dropped their price target on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a report on Wednesday, October 23rd. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. TD Cowen reduced their price target on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Wedbush reiterated an “outperform” rating and set a $181.00 target price on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Finally, Stifel Nicolaus lifted their target price on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $192.07.

Ascendis Pharma A/S Price Performance

NASDAQ ASND opened at $127.49 on Wednesday. The stock’s 50 day simple moving average is $133.25 and its 200 day simple moving average is $133.30. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $161.00. The firm has a market cap of $7.74 billion, a PE ratio of -15.78 and a beta of 0.65.

Hedge Funds Weigh In On Ascendis Pharma A/S

Institutional investors and hedge funds have recently made changes to their positions in the stock. Groupama Asset Managment bought a new position in Ascendis Pharma A/S during the third quarter valued at approximately $60,000. Janus Henderson Group PLC increased its holdings in Ascendis Pharma A/S by 6.8% during the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after buying an additional 267,881 shares during the last quarter. Westfield Capital Management Co. LP increased its stake in shares of Ascendis Pharma A/S by 3.4% in the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after purchasing an additional 170,942 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Ascendis Pharma A/S by 9.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock worth $278,760,000 after purchasing an additional 155,971 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. purchased a new stake in shares of Ascendis Pharma A/S in the third quarter worth $19,908,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.